Esperion Therapeutics (ESPR) Price Target Raised to $121.00

Marco Green
April 22, 2018

Its down 0.34, from 1.67 in 2017Q3. 238.43 million shares or 0.16% less from 238.82 million shares in 2017Q3 were reported. Also, the number of active investment managers holding Aberdeen Indonesia Fund Inc in top ten stock positions was flat from 0 to 0 for the same number. Sold All: 40 Reduced: 158 Increased: 101 New Position: 66. BB&T Securities LLC purchased a new stake in Esperion Therapeutics in the fourth quarter valued at about $263,000. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.80) by $0.36.

In other Esperion Therapeutics news, Director Nicole Vitullo sold 11,674 shares of the stock in a transaction dated Thursday, January 25th. The stock decreased 0.63% or $0.47 during the last trading session, reaching $73.69. On Wednesday, February 21 JP Morgan maintained the shares of ESPR in report with "Neutral" rating. ESPR outperformed by 78.31% the S&P500. (NASDAQ:ESPR). D E Shaw & has 0% invested in Esperion Therapeutics, Inc. The company has a market cap of $1,967.84, a price-to-earnings ratio of -10.85 and a beta of 2.51. The Company's lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. It now has negative earnings.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Tuesday, February 20th. Therefore 56% are positive. Since November 22, 2017 according to StockzIntelligence Inc Esperion has 16 analyst reports. The firm earned "Buy" rating on Thursday, April 19 by Northland Capital. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR). Rothschild Asset Mngmt Inc owns 20,871 shares for 0.01% of their portfolio. On Thursday, December 14 the stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) or 10,769 shs. (NASDAQ:ESPR) to "Hold" rating. On Monday, March 19 the stock of Esperion Therapeutics, Inc. Wells Fargo & Company MN now owns 14,519 shares of the biopharmaceutical company's stock worth $728,000 after acquiring an additional 2,917 shares during the period. On Tuesday, March 27 the company was maintained by Cowen & Co. The company now has a consensus rating of "Buy" and an average target price of $92.54. (NASDAQ:ESPR) has "Buy" rating given on Monday, October 26 by Lake Street. The company was maintained on Wednesday, February 21 by Needham. The firm earned "Buy" rating on Wednesday, March 7 by Cowen & Co.

Investors sentiment decreased to 1.33 in Q4 2017. It's up 0.26, from 1.17 in 2017Q3. 93 funds opened positions while 226 raised stakes. Finally, OxFORD Asset Management LLP bought a new stake in shares of Esperion Therapeutics during the 3rd quarter worth approximately $715,000. (NASDAQ:ESPR). 26,747 were reported by California State Teachers Retirement. Jpmorgan Chase And reported 82,261 shares or 0% of all its holdings. The Hikari Power Ltd holds 165,650 shares with $21.13M value, up from 160,800 last quarter. The company was initiated on Tuesday, December 1 by Liberum Capital. Weiss Asset Mgmt Lp owns 5,427 shs for 0.03% of their capital. Moreover, Perigon Wealth Management Limited Liability has 0.04% invested in Esperion Therapeutics, Inc. FINRA published in April ESPR's total 3.46 million shares shorted. Fmr Ltd Limited Liability Company holds 0.01% or 1.25 million shares in its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) holds 1,168 shares. Zacks Investment Research's EPS averages are an average based on a survey of analysts that follow Esperion Therapeutics. (NASDAQ:ESPR) or 39,528 shs. Chardan Capital Markets maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR). First Mercantile Trust holds 4,233 shares or 0.05% of its portfolio. Sg Americas Secs Limited Company has 0% invested in Esperion Therapeutics, Inc.

The stock decreased 2.32% or $0.92 during the last trading session, reaching $38.72. At the end of 2017Q4, the hedge fund run by Hal Mintz held 142,185 shares of the health care company, valued at $9.36M, up from 83,357 at the end of the previous reported quarter. CF Industries Holdings, Inc. (NYSE:FBM) has 0.00% since April 20, 2017 and is. It has outperformed by 0.48% the S&P500.

Ratings analysis reveals 50% of CF Industries's analysts are positive. Six analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. United Technologies Corporation has $167.0 highest and $100 lowest target. The stock was sold at an average price of $71.79, for a total value of $838,076.46. CF was included in 4 notes of analysts from August 18, 2016. RBC Capital Markets downgraded CF Industries Holdings, Inc. As per Wednesday, August 9, the company rating was upgraded by Jefferies. "Buy" rating has 7, "Sell" are 0, while 4 are "Hold". The stock has "Buy" rating by Bank of America on Friday, January 5. The rating was maintained by Barclays Capital on Thursday, August 18 with "Overweight". The company has market cap of 28.22 million GBP. The firm operates through Ammonia, Granular Urea, UAN, AN, Other, and Phosphate divisions. Metropolitan Life Insurance New York holds 5,474 shs or 0% of its capital. Two Sigma Llc holds 0.01% of its portfolio in General Motors Company (NYSE:GM) for 6,555 shares.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER